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Abstract
Antibody-based therapeutics targeting CNS antigens emerge as promising treatments in neurology. However, access to the CNS is
limited by the blood–brain barrier. We examined the effects of a neurite growth-enhancing anti-Nogo A antibody therapy following
3 routes of administration—intrathecal (i.t.), intravenous (i.v.), and subcutaneous (s.c.)—after large photothrombotic strokes in adult
rats. Intrathecal treatment of full-length IgG anti-Nogo A antibodies enhanced recovery of the grasping function, but intravenous or
subcutaneous administration had no detectable effect in spite of large amounts of antibodies in the peripheral circulation. Thus, in
contrast to intravenous and subcutaneous delivery, intrathecal administration is an effective and reliable way to target CNS antigens.
Our data reveal that antibody delivery to the CNS is far from trivial. While intrathecal application is feasible and guarantees
defined antibody doses in the effective range for a biological function, the identification and establishment of easier routes of
administration remains an important task to facilitate antibody-based future therapies of CNS disorders.
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Introduction
Antibodies targeting CNS antigens were shown to be promis-
ing novel therapeutic tools for diseases like Alzheimer’s and
Parkinson’s diseases, multiple sclerosis, stroke, and spinal
cord injury [1]. The route of application in recent clinical trials
was mostly intravenous (i.v.). Due to the blood–brain barrier,
very low proportions of antibodies reach the CNS parenchy-
ma. To overcome this biological barrier, very large doses of
antibodies were applied in these studies (up to grams per in-
jection [2, 3]). The negative outcome of several recent clinical
trials, e.g., in Alzheimer’s disease, may well in part be due to
insufficient amounts of therapeutic antibodies reaching the
CNS.
Intrathecally or intracerebroventricularly applied, function-
blocking antibodies against the neurite growth-inhibiting and
plasticity-restricting membrane protein Nogo A and its recep-
tors have been shown in various laboratories in different
stroke and spinal cord injury animal models to enhance regen-
erative and compensatory sprouting as well as functional re-
covery in rodents and primates [4, 5]. A phase I clinical trial in
spinal cord-injured patients has shown intrathecal human anti-
human Nogo A antibody injection or infusion over 30 days to
be safe [4]. A randomized double-blind placebo-controlled
phase II clinical trial is ongoing (https://clinicaltrials.gov/ct2/
show/NCT03935321). However, for broader clinical
applications, e.g., in stroke patients, a systemic rather than
an intrathecal application would be preferable. The same is
true for other therapeutic antibodies and neurological
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indications, especially if long-term treatments in outpatients
are required. Here, we compare intrathecal, intravenous, and
subcutaneous administrations of a therapeutic antibody
against the neurite growth inhibitor Nogo A in adult rats with
large forebrain strokes in their ability to restore forelimb fine
motor function.
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Methods
Animals
A total of 57 adult female Long–Evans rats (200-250 g, 12-
16 weeks old, Janvier, Le Genest-Saint-Isle, France) were
included. The animals were housed in groups of 2 to 4 in open
airflow cages under a 12-h dark/light cycle. Food and water
were delivered ad libitum except for restricted periods during
the single-pellet grasping and staircase training and testing
phases. All experimental procedures were approved by the
Veterinary Office of the canton of Zurich, Switzerland.
Experimental Setup
All of the rats were first handled and then trained in the single-
pellet grasping task as previously described [6, 7]. A large
photothrombotic stroke [7] lesioned the sensorimotor cortex
corresponding to the preferred paw of the animals in the grasp-
ing task. Only those animals with a significant lesion deficit
(< 50% success rate in the grasping task compared to
prestroke baseline levels) 2 days after stroke surgery and same
lesion size and location (see below) were included (n = 41).
The animals were then randomized into 6 different treatment
groups (Fig. 1A): the animals in the “anti-Nogo i.t.” group
received 8.4 mg/2 ml anti-Nogo antibody 11C7 [8] intrathe-
cally via osmotic pump delivery into the lumbar CSF space
until 14 days after stroke [6, 7]. In the “anti-Nogo i.v.” group,
the animals were injected twice with 42 mg anti-Nogo anti-
bodies (diluted in 5.6-6 ml PBS, depending on the antibody
batch) over the course of 1 h into the femoral vein on days 2 or
3 and 7 to 8 after insult. Control animals received instead of
antibodies intravenous injections of 5.6 to 6 ml PBS (“PBS
i.v.” group). For the subcutaneous antibody application (“anti-
Nogo s.c.” and “control IgG s.c.” groups), 1 ml of antibody
solution (10 mg/ml anti-Nogo or control (FG12/B5) antibod-
ies) was subcutaneously injected over the flank (alternating
the side) starting on day 3 after stroke with 2 applications daily
for days 2/3 to 5 (morning and evening with 12 h delay in
between) followed by 1 injection per day up to day 12.
Animals in the “spontaneous recovery” group received no
treatment after stroke. To assess the degree of recovery of lost
forelimb function, the animals were retested in the single-
pellet grasping task on days 14, 21, and 28 after stroke. We
also exposed the animals to novel (nontrained) tasks (sugar-
pellet grasping in staircase, horizontal ladder, and narrow
beam, as previously described [6, 7]), testing their overall
functional recovery. Blood was taken to measure the antibody
concentration on day 2/3, 7/8, 9/10, and 14 after stroke. For
the intravenous and subcutaneous groups, blood was collected
always before the next dose of antibody application on these
days. Finally, the rats were transcardially perfused [6, 7].
To determine the tissue antibody concentration in the CNS,
the animals either received 4.2 mg/ml anti-Nogo antibody
11C7 [8] intrathecally via continuous osmotic pump delivery
into the lumbar CSF space (n = 5) starting on day 2 after stroke
or were injected with 42 mg anti-Nogo antibodies over the
course of 1 h into the femoral vein on day 2 after insult (n =
5). Both groups of animals were euthanized, CSF was taken
from the cisterna magna, and the rats were perfused with ice-
cold Ringer solution 7 days after stroke, followed by dissec-
tion and removal of brain and spinal cord tissues (lumbar
spinal cord, thoracic spinal cord, cervical spinal cord, cerebel-
lum, brainstem, stroke penumbra (1-2 mm around the stroke
core), cortex (stroke side)). The tissues were immediately fro-
zen at − 80° in liquid nitrogen for further tissue analysis with
enzyme-linked immunosorbent assays (ELISAs) (see below).
Except for n = 4 animals, CSF samples contained traces of
blood and were thus not used for further analysis. All the
animals were number-coded, and investigators responsible
for the behavioral assessments, analysis, and interpretation
of the data were blinded to the treatment groups until the
end of the data analysis. This study followed the ARRIVE
guidelines (https://www.nc3rs.org.uk/arrive-guidelines).
Determination of Stroke Lesion Size
Lesion size and location were determined ex vivo in the per-
fused brains with a 7-T small animal MR system (Bruker
BioSpin GmbH, Ettlingen, Germany) as previously described
[7] on 20 T2-weighted frontal plane slices (thickness, 0.3 mm;
interslice distance, 0.3 mm (no gap between slices)). The final
calculations for the stroke lesion size were performed with
Fig. 1 Intrathecal anti-Nogo application promotes functional recovery
after stroke while intravenous and subcutaneous application routes fail.
(A) Experimental timeline for the 6 experimental groups (“anti-Nogo i.t.,”
n = 11; “anti-Nogo i.v.,” n = 8; “anti-Nogo s.c.,” n = 7; “PBS i.v.,” n = 6;
“control IgG s.c.,” n = 5; “spontaneous recovery,” n = 4). The graph in
particular depicts the frequency of the anti-Nogo antibody dosage through
different routes of application (i.t., i.v., and s.c.) early after
photothrombotic stroke in rats (treatment window 2-3 days till 14 days
after insult). (B) Success rates in the single-pellet grasping task: Only the
animals which had received anti-Nogo antibodies intrathecally (“anti-
Nogo i.t.” group) showed a significant recovery 3 to 4 weeks after stroke.
(C) The animals in the “anti-Nogo i.t.” group also performed better than
all other groups in a second, novel grasping task (staircase test), intro-
duced after the immunotherapy. The animals with the anti-Nogo intrathe-
cal application in particular significantly exceeded the animals with sub-
cutaneous application and those without treatment (“spontaneous recov-
ery group”). The same effect could not be found for more general loco-
motion tasks such as the horizontal ladder and the narrow beam test. (D)
Left: representative coronal MR image depicting the lesioned motor cor-
tex in a rat brain 8 weeks after stroke, scale bar = 1000 μm. Right: stroke
lesion size in all 6 treatment groups revealed no significant difference
among groups. Data are presented as means ± SEM; statistical evaluation
was carried out with 1-way (C, D) and 2-way ANOVA (B) repeated
measure followed by Bonferroni post hoc; asterisks indicate signifi-
cances: *P < 0.05, **P < 0.01, ***P < 0.001. n.s. = nonsignificant
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Image J comparing the lesioned hemisphere to the intact one
[7]. Only animals with a similar, large lesion size (> 8.0 mm3)
and location destroying the sensorimotor cortex as determined
by the MRI data were included (n = 41 of 47 rats).
Detection of Infused Anti-Nogo A Abs in Serum, CSF,
and CNS Tissue by ELISA
The tissue was homogenized in a weight-to-volume ratio of 1:3
in modified lysis buffer containing 200 mM sodium chloride,
20 mM Tris-HCl, pH 8.0, 1% NP-40, 1 mM EDTA, and prote-
ase inhibitors (Roche, Basel, Switzerland). The homogenatewas
centrifuged (16.000 rcf) to pellet the cell and tissue debris (max-
imally 15-25% of the total homogenate). The protein concentra-
tion in the supernatant (between 75 and 85% of the total homog-
enate) was measured with the RC-DC Protein Assay Kit (Bio-
Rad, Hercules, CA). The concentration of anti-Nogo A antibod-
ies in serum, CSF, and CNS tissue was measured with a sand-
wich enzyme-linked immunosorbent assay. Briefly, plates
were coated with rabbit anti-mouse IgG (Invitrogen,
Carlsbad, CA) as the primary antibody and blocked
using 5% w/v skimmed milk powder in TBS-T buffer
(Tris-buffered saline, 0.1% Tween 20) followed by in-
cubation of samples. To detect the anti-Nogo A antibod-
ies in samples, a HRP-conjugated goat anti-mouse IgG
(Invitrogen) secondary antibody was used. The activity
of horseradish peroxidase (HRP) was determined by a
Pierce TMB ELISA Substrate kit (Thermo Scientific,
Waltham, MA), and optical density of the HRP reaction
was de t e rm ined a t 450 nm us ing a TECAN
SPARK reader. The concentrations of anti-Nogo A an-
tibodies in serum, CSF, and CNS tissue were then plot-
ted against a standard curve of anti-Nogo A antibody.
Statistical Analysis
Statistical evaluation was performed with Graph Pad Prism
(GraphPad Software Inc.; Version 6.05). All data are
expressed as means ± SEM. Group-dependent data with sev-
eral time points were analyzed using 2-way repeated-mea-
sures ANOVA and Bonferroni’s post hoc test for the results
of the single-pellet grasping. We chose a Bonferroni post hoc
test due to the slightly unbalanced data set (different group
sizes). One-way ANOVA repeated measures plus
Bonferroni’s multiple-comparison tests was applied in the
case of time-independent group values (lesion size analysis,
novel tasks, and antibody concentrations comparing different
tissues). The sample size for the different treatment groups
was estimated by means and variance of measured data means
in related work [6, 7, 9] predicted to be sufficient to detect a
statistically significant result in ANOVA with α = 0.05 and
power > 0.8. The level of significance was set at *P < 0.05,
**P < 0.01, ***P < 0.001.
Results
We compared an intrathecal anti-Nogo A antibody treatment
over 2 weeks by lumbar pumps with intravenous (i.v.) and
subcutaneous (s.c.) application routes with much larger quan-
tities (10× for i.v., 15× for s.c.) to promote functional recovery
after a large photothrombotic stroke in rats destroying the
sensorimotor cortex (Fig. 1A). We found that precise grasping
for sugar pellets through a window in the Plexiglas testing box
(Fig. 1B) was destroyed in all groups 2 days after stroke (10-
20% of baseline levels in all groups). The animals which re-
ceived anti-Nogo antibodies (8.4 mg/2 ml) intrathecally, from
day 2/3 to 14, via osmotic pumps revealed a significantly
higher success rate in the pellet grasping task already 2 weeks
after stroke compared to animals without treatment (“anti-
Nogo i.t.” vs “spontaneous recovery” group, repeated-
measures 2-way ANOVA with post hoc Bonferroni,
P < 0.05, Fig. 1B). The animals with the intrathecal anti-
Nogo treatment subsequently excelled compared to the other
groups from 3 weeks onward (Fig. 1B). In contrast, the intra-
venous and subcutaneous applications of the anti-Nogo ther-
apy failed to enhance the stroke-impaired grasping function
compared to the control IgG, PBS, or untreated groups (Fig.
1B), although the applied anti-Nogo dosage was 10 times (for
i.v.) and 15 times (for s.c.) higher than in the intrathecal con-
dition. A tendency for improved recovery may be present in
the intravenous anti-Nogo group, but results did not reach
significance (in part due to the high variation inherent in these
complex behavioral assays). The persistent low performance
level of the “anti-Nogo s.c.” group was particularly remark-
able, but correlated with the low serum levels of the antibodies
(see below) (“anti-Nogo s.c.” vs “anti-Nogo i.t.” cohort 3 to
4 weeks after insult, repeated-measures 2-way ANOVA with
post hoc Bonferroni, P < 0.01, Fig. 1B).
The animals with the intrathecal anti-Nogo application per-
formed also best in another grasping task—the staircase test
(Fig. 1C, success rate 41.3% ± 4.7 for the “anti-Nogo i.t.”
animals vs 14.2% ± 1.9 for the “anti-Nogo s.c.” group vs
10.5% ± 3.0 for the “spontaneous recovery” group). As the
animals were not trained in the staircase test, this result indi-
cates a generalization of recovery for grasping function in the
“anti-Nogo i.t.” group which is transferable to nontrained
grasping tasks. However, when the animals were tested in 2
other novel tasks assessing general locomotion and balance—
the horizontal ladder and the narrow beam—we did not find a
specific effect of the anti-Nogo immunotherapy on the level of
success compared to the control groups (Fig. 1C): although
the animals with subcutaneous anti-Nogo treatment per-
formed significantly better than the animals without treatment
on the narrow beam (“anti-Nogo s.c. vs “spontaneous recov-
ery” group, 1-way ANOVA with post hoc Bonferroni,
P < 0.01, Fig. 1C), the same was true for the “IgG control
s.c.” group. This result may point to a slightly compromised
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locomotion in animals with intrathecal and intravenous treat-
ments due to scars and sutures from the implanted osmotic
pump or the femoral vein injections. Ex vivoMRI at the end of
the behavioral testing revealed the same stroke lesion size and
location for all animals included in the analysis (Fig. 1D).
ELISA analysis of plasma anti-Nogo A antibody concen-
trations revealed that antibodies applied intrathecally reached
the peripheral circulation from the CNS compartment where
they slowly accumulated (Fig. 2A). This is in line with the
documented half-life of antibodies in the CSF of 1 to 2 days
[10, 11]. Intravenous application of anti-Nogo A antibodies
resulted in high values after the first and second bolus injec-
tions (Fig. 2A). In contrast, daily subcutaneous injections led
to a surprisingly slow increase of the anti-Nogo A antibody
levels in the circulation withmaximal levels far below those of
the intravenous injections (Fig. 2A). This result indicates a
poor transfer of the antibody from the subcutaneous space
on the back of the animals into the systemic circulation. We
then compared anti-Nogo antibody concentrations in the CSF






























































































































































































































Fig. 2 Plasma, CSF, and CNS tissue concentrations of anti-Nogo anti-
bodies depending on the route of administration. (A) Plasma levels of
anti-Nogo A antibody after intravenous (n = 8), intrathecal, (n = 11), or
subcutaneous, (n = 7) application together with control IgG subcutaneous
(n = 5) or intravenous (n = 6) PBS. (B) Antibody concentration in CSF
7 days after stroke in animals with intravenous bolus injection of 42 mg
anti-Nogo antibody (n = 2) on day 2 after stroke versus continuous intra-
thecal application (4.2 mg) via osmotic pump (n = 2) starting from day 2
after stroke. (C, D) Antibody concentration in different CNS regions
7 days after stroke depending on intravenous bolus injection (42 mg) on
day 2 after insult (C) or continuous intrathecal pump infusion (4.2 mg)
starting from day 2 after stroke (D). (E) Table depicting the percentage of
antibody reaching the respective tissue region relative to the total amount
of applied intravenous or intrathecal antibody. We also calculated the
percentage of antibody penetration relative to the total amount of injected
antibody for the whole brain wet weight as well as for the spinal cord.
Data are presented as mean values of antibody concentrations (μg/ml or
μg/g wet weight) measured in serum, CSF, and CNS tissue with SEM.
Statistical evaluation was carried out with 1-way (C) ANOVA repeated
measure followed by Bonferroni post hoc; asterisks indicate signifi-
cances: ***P < 0.001
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intrathecal (via osmotic pump) or intravenous bolus injection
of the antibody. Although the amount of intravenously
injected antibody was 10× higher than the intrathecally in-
fused amount, anti-Nogo antibody levels in the CSF were
100× higher in animals with the intrathecal route of adminis-
tration (Fig. 2B). While a relatively high dose of tissue anti-
body concentration was measured in the penumbra of animals
having received the intravenous bolus injection (40.6 ±
3.6 μg/g wet weight, Fig. 2C), all other parts of the CNS
had much lower antibody concentrations (1.9-7.5μg/g wet
weight). The proportion of intravenously injected antibodies
reaching the CNS (outside of the stroke penumbra) was in the
range of 0.001 to 0.004% (Fig. 2E). In contrast to the intrave-
nously injected rats, the animals with intrathecal pumps
showed a gradient of antibody tissue concentrations along
the spinal cord with the highest values in the lumbar spinal
cord (64.8 ± 18.6μg/g wet weight) and decreasing levels up to
the brain (Fig. 2D). For the other brain compartments mea-
sured, we found an antibody content about 0.02 to 0.04% of
the total intrathecally infused anti-Nogo A antibody (Fig. 2E).
For the average whole brain wet weight, we calculated 0.19%
of infused antibody penetration (Fig. 2E). Tissue anti-
body retention after 7 days of intrathecal pump infusion
was therefore 3.8× higher in the brain tissue and > 67×
higher in the spinal cord than a 10× larger intravenous
injection (Fig. 2E).
Discussion
We find that an acute, 2-week intrathecal application of anti-
Nogo A antibodies resulted in a recovery level of skilled fore-
limb function after a large sensory–motor cortex stroke in
adult rats of about 40%, whereas the control groups had poor
recovery levels of 10 to 25%. These results are in line with
earlier studies where intrathecal control antibodies were com-
pared to anti-Nogo A antibodies [9]. Importantly, no signifi-
cant improvements of skilled forelimb reaching were ob-
served in the animals injected with anti-Nogo A antibodies
intravenously or subcutaneously. The high peripheral anti-
body levels also did not enhance the damage as shown by
comparison with the PBS and the untreated groups. The intra-
thecal anti-Nogo effect was specific for the trained task—food
pellet grasping—underlining the role of training in functional
recovery after stroke [6]. In the untrained ladder crossing test,
intravenous anti-Nogo-treated rats showed a tendency for a
positive outcome, perhaps due to small amounts of antibodies
reaching the CNS from the very high plasma levels.
Surprisingly, after subcutaneous injections, plasma levels of
antibodies rose only very slowly and never reached the levels
seen after intravenous injection, in spite of the higher amounts
injected. Unspecific, high-capacity binding must have oc-
curred in the subcutaneous compartment with poor uptake
and only slow release into the circulation. Therapeutic anti-
bodies targeting CNS antigens are of high current interest for a
number of neurological diseases. Easy routes of application
would be highly desirable. However, the present data show a
clear superiority of application by the intrathecal route directly
into the CNS over high doses applied peripherally. We find a
relative tissue antibody concentration of ~ 0.5 to 0.8% of the
intrathecally infused antibody in the CNS, a concentration that
was sufficient to promote fiber rearrangement and functional
recovery. Our results are also in line with tissue concentration
studies after intrathecal antibody delivery in other animal
models [12] as well as in humans [4]. Following intravenous
bolus injection, we retrieved 0.007 to 0.05% of the intrave-
nously applied anti-Nogo antibody in the CNS parenchyma.
Similar results were found in earlier studies [3, 13, 14]. This
proportion may be slightly increased by local inflammatory
events, e.g., MS foci or inflamed AD plaque regions in the
CNS, which might locally compromise the BBB [3, 15, 16].
Here, however, the large stroke lesions did not provide suffi-
cient BBB breakdown to allow antibody penetration to the
extent that the plasticity and repair functions of anti-Nogo A
would have become apparent. Several recent clinical trials
with intravenously applied therapeutic antibodies failed to
reach the expected results, in spite of a strong scientific basis
and preclinical results [2, 16, 17]. Poor, individually variable
antibody penetration into the CNS may well have played an
important role for these failures. Strategies to enhance delivery
of systemically administered exogenous antibodies to the
CNS such as transient disruption of the BBB with focused
ultrasound [18, 19] or shuttling constructs across the BBB
[20–22] are being developed but have not stood the tests for
clinical routine yet.
Our study reveals that antibody delivery to the CNS re-
mains challenging. While the intrathecal application guaran-
tees defined antibody doses in the effective range for a bio-
logical function, strong efforts must be taken to identify and
establish easier routes of administration to successfully treat
CNS disorders with antibody-based future therapies.
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